(Total Views: 170)
Posted On: 08/16/2023 12:06:53 PM
Post# of 127176
EG.5, nicknamed "Eris," has taken over as the dominant variant in the U.S., causing 17.3% of COVID cases so far this month, according to the Centers for Disease Control and Protection (CDC).
Privately, CDC scientists are calling the new Covid variant Billy Bob as they expect, as before, the virus will chow down on the unvaxxed throughout Trumpistan, where Covid acts as though it's a giant Applebee's.....'where eatin's good in the neighborhood!'
As COVID-19 vaccine makers gear up to launch updated shots in the private market, can the new vaccines keep up with the virus?
By Zoey BeckerAug 15, 2023 11:09am
https://www.fiercepharma.com/pharma/covid-19-...keep-virus
COVID-19PfizerModernaNovavax
COVID vaccine
Pfizer, Moderna and Novavax have previously pegged vaccine prices in the private market at around $130 per dose. (Diy13/iStock/Getty Images Plus)
After the recent cratering of COVID-19 vaccine demand, biopharma's pandemic superstars are looking to bounce back with private-market launches this fall.
Meanwhile, the evolving nature of the virus presents a need for vaccines that can offer protection against new variants. And even as Pfizer, Moderna and Novavax wait for the FDA to sign off on their tweaked vaccines, a new virus variant has taken hold.
EG.5, nicknamed "Eris," has taken over as the dominant variant in the U.S., causing 17.3% of COVID cases so far this month, according to the Centers for Disease Control and Protection (CDC).
Eris has spread to 51 countries and has been named as a “variant of interest” by the World Health Organization (WHO). It's an offshoot of another variant called XBB.1.9.2.
Pfizer, Moderna and Novavax's updated vaccines are set to target the XBB.1.5 variant and are expected to launch shortly ahead of the fall vaccination season.
Privately, CDC scientists are calling the new Covid variant Billy Bob as they expect, as before, the virus will chow down on the unvaxxed throughout Trumpistan, where Covid acts as though it's a giant Applebee's.....'where eatin's good in the neighborhood!'
As COVID-19 vaccine makers gear up to launch updated shots in the private market, can the new vaccines keep up with the virus?
By Zoey BeckerAug 15, 2023 11:09am
https://www.fiercepharma.com/pharma/covid-19-...keep-virus
COVID-19PfizerModernaNovavax
COVID vaccine
Pfizer, Moderna and Novavax have previously pegged vaccine prices in the private market at around $130 per dose. (Diy13/iStock/Getty Images Plus)
After the recent cratering of COVID-19 vaccine demand, biopharma's pandemic superstars are looking to bounce back with private-market launches this fall.
Meanwhile, the evolving nature of the virus presents a need for vaccines that can offer protection against new variants. And even as Pfizer, Moderna and Novavax wait for the FDA to sign off on their tweaked vaccines, a new virus variant has taken hold.
EG.5, nicknamed "Eris," has taken over as the dominant variant in the U.S., causing 17.3% of COVID cases so far this month, according to the Centers for Disease Control and Protection (CDC).
Eris has spread to 51 countries and has been named as a “variant of interest” by the World Health Organization (WHO). It's an offshoot of another variant called XBB.1.9.2.
Pfizer, Moderna and Novavax's updated vaccines are set to target the XBB.1.5 variant and are expected to launch shortly ahead of the fall vaccination season.
(1)
(0)
